Cure My Disease

Don't miss your cure!

 Log in / Sign up

Race for better blood cancer treatment: can new drug combo extend lives?

NCT ID NCT04266301

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding an experimental drug called MBG453 to the standard treatment (azacitidine) could help adults with higher-risk forms of myelodysplastic syndromes (MDS) or a related blood cancer (CMML-2). The main goal was to see if the combination helped patients live longer compared to the standard treatment alone. The study also looked at whether the treatment improved quality of life, reduced the need for blood transfusions, and controlled the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hackensack University Medical Ctr

    Hackensack, New Jersey, 07601, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Novartis Investigative Site

    Pilar, Buenos Aires, B1629AHJ, Argentina

  • Novartis Investigative Site

    Wooloongabba, Queensland, 4102, Australia

  • Novartis Investigative Site

    Clayton, Victoria, 3168, Australia

  • Novartis Investigative Site

    Perth, Western Australia, 6000, Australia

  • Novartis Investigative Site

    Innsbruck, Tyrol, 6020, Austria

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Linz, 4020, Austria

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, 8800, Belgium

  • Novartis Investigative Site

    Brasschaat, 2930, Belgium

  • Novartis Investigative Site

    Florianópolis, Santa Catarina, 88020-210, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 04014-002, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 05319-000, Brazil

  • Novartis Investigative Site

    Calgary, Alberta, T2N 4N2, Canada

  • Novartis Investigative Site

    Toronto, Ontario, M4N 3M5, Canada

  • Novartis Investigative Site

    Viña del Mar, Región de Valparaíso, 2540364, Chile

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510080, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, 518037, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430022, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430030, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004, China

  • Novartis Investigative Site

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310003, China

  • Novartis Investigative Site

    Beijing, 100029, China

  • Novartis Investigative Site

    Beijing, 100730, China

  • Novartis Investigative Site

    Jinan, 250012, China

  • Novartis Investigative Site

    Shanghai, 200025, China

  • Novartis Investigative Site

    Shanghai, 200233, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Tianjin, 300052, China

  • Novartis Investigative Site

    Rionegro, Antioquia, 054047, Colombia

  • Novartis Investigative Site

    Bogotá, 110231, Colombia

  • Novartis Investigative Site

    Brno, 625 00, Czechia

  • Novartis Investigative Site

    Hradec Králové, 500 05, Czechia

  • Novartis Investigative Site

    Prague, 128 00, Czechia

  • Novartis Investigative Site

    Prague, 128 08, Czechia

  • Novartis Investigative Site

    Helsinki, FIN 00290, Finland

  • Novartis Investigative Site

    Kuopio, 70211, Finland

  • Novartis Investigative Site

    Grenoble, 38043, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Tours, 37044, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, 54511, France

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Velbert, North Rhine-Westphalia, 42551, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Augsburg, 86179, Germany

  • Novartis Investigative Site

    Düsseldorf, 40479, Germany

  • Novartis Investigative Site

    Greifswald, 17475, Germany

  • Novartis Investigative Site

    Kiel, 24116, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

  • Novartis Investigative Site

    Alexandroupoli, 681 00, Greece

  • Novartis Investigative Site

    Pátrai, 265 04, Greece

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380009, India

  • Novartis Investigative Site

    Faridabad, Haryana, 121 001, India

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625107, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700014, India

  • Novartis Investigative Site

    Kolkata, West Bengal, 700160, India

  • Novartis Investigative Site

    Delhi, 110085, India

  • Novartis Investigative Site

    Afula, 1834111, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Catania, CT, 95123, Italy

  • Novartis Investigative Site

    Florence, FI, 50134, Italy

  • Novartis Investigative Site

    Genova, GE, 16132, Italy

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Reggio Calabria, RC, 89124, Italy

  • Novartis Investigative Site

    Roma, RM, 00133, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 464 8681, Japan

  • Novartis Investigative Site

    Kashiwa, Chiba, 277 8577, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 812-8582, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 064 0804, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, 259-1193, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    Sakai, Osaka, 590-0197, Japan

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Novartis Investigative Site

    Yamagata, Yamagata, 990 9585, Japan

  • Novartis Investigative Site

    Osaka, 545-8586, Japan

  • Novartis Investigative Site

    Beirut, 113-0236, Lebanon

  • Novartis Investigative Site

    Vilnius, LT-08406, Lithuania

  • Novartis Investigative Site

    George Town, Pulau Pinang, 10450, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Novartis Investigative Site

    Kuala Selangor, 68000, Malaysia

  • Novartis Investigative Site

    Satélite, Edo Mexico, 53100, Mexico

  • Novartis Investigative Site

    Mexico City, Mexico City, 06720, Mexico

  • Novartis Investigative Site

    Morelia, Michoacán, 58260, Mexico

  • Novartis Investigative Site

    Estado de México, 52787, Mexico

  • Novartis Investigative Site

    Groningen, Provincie Groningen, 9713 GZ, Netherlands

  • Novartis Investigative Site

    Khoudh, 123, Oman

  • Novartis Investigative Site

    Lisbon, 1099-023, Portugal

  • Novartis Investigative Site

    Porto, 4200-072, Portugal

  • Novartis Investigative Site

    Saint Petersburg, 191024, Russia

  • Novartis Investigative Site

    Saint Petersburg, 197022, Russia

  • Novartis Investigative Site

    Riyadh, 11211, Saudi Arabia

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    Badalona, Barcelona, 08916, Spain

  • Novartis Investigative Site

    Salamanca, Castille and León, 37007, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Oviedo, Principality of Asturias, 33011, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Seville, 41013, Spain

  • Novartis Investigative Site

    Valencia, 46010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

  • Novartis Investigative Site

    Hualien City, 970, Taiwan

  • Novartis Investigative Site

    Kaohsiung City, 83301, Taiwan

  • Novartis Investigative Site

    Liouying Township, 736005, Taiwan

  • Novartis Investigative Site

    Taichung, 40447, Taiwan

  • Novartis Investigative Site

    Taipei, 10002, Taiwan

  • Novartis Investigative Site

    Taoyuan District, 33305, Taiwan

  • Novartis Investigative Site

    Songkhla, Hat Yai, 90110, Thailand

  • Novartis Investigative Site

    Khon Kaen, THA, 40002, Thailand

  • Novartis Investigative Site

    Bangkok, 10330, Thailand

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Chiang Mai, 50200, Thailand

  • Novartis Investigative Site

    Samsun, Atakum, 55200, Turkey (Türkiye)

  • Novartis Investigative Site

    Edirne, Merkez, 22030, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Pendik, 34899, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Izmir, 35100, Turkey (Türkiye)

  • Novartis Investigative Site

    Portsmouth, Hants, PO6 3LY, United Kingdom

  • Novartis Investigative Site

    Edinburgh, Scotland, EH4 2XU, United Kingdom

  • Novartis Investigative Site

    Manchester, M20 2BX, United Kingdom

  • Novartis Investigative Site

    Nottingham, NG5 1PB, United Kingdom

  • University Of Miami

    Miami, Florida, 33136, United States

  • University of California LA

    Los Angeles, California, 90095, United States

  • University of Rochester Medical Ctr

    Rochester, New York, 14642, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

  • Weill Cornell Medicine NY-Presb

    New York, New York, 10021, United States

  • Yale University School Of Medicine

    New Haven, Connecticut, 06520, United States

  • Yuma Regional Cancer Center

    Yuma, Arizona, 85364, United States

Conditions

Explore the condition pages connected to this study.

LEUKEMIA, MYELOMONOCYTIC, CHRONIC MYELODYSPLASTIC SYNDROMES